Lab
Ace Biomedical Labs, LLC
Ace Biomedical Labs, LLC was paid $222K by Medicaid between Jun 2018 and Dec 2024, across 21 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 72% of everything it billed.
33Billing provider infoACE BIOMEDICAL LABS, LLC
JACKSONVILLE, FL 32216
JACKSONVILLE, FL 32216
33aNPI1750839262assigned 09/13/2016
33bProvider typeClinical Medical Laboratory
28Total paid$222K
24GClaims19,744
24DCodes billed21
24AFirst – last monthJun 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#78 of 225
Median peer was paid$74K
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 755 | $0.00 | |
| 2019 | 1,100 | $35.17 | |
| 2020 | 1,674 | $20K | |
| 2021 | 7,527 | $97K | |
| 2022 | 4,859 | $79K | |
| 2023 | 2,885 | $21K | |
| 2024incomplete | 944 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 72% | 4,780 | 2,826 | $160K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8.3% | 4,210 | 2,497 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.7% | 2,644 | 2,063 | $17K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 5.1% | 2,004 | 1,578 | $11K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.6% | 3,463 | 2,115 | $10K |
| 87631 | 1.8% | 54 | 26 | $4K | |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 1,147 | 1,105 | $640.32 |
| 87498 | <1% | 53 | 25 | $192.06 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 44 | 18 | $105.38 |
| 87634 | <1% | 44 | 18 | $46.97 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 45 | 19 | $42.28 |
| 87503 | <1% | 43 | 18 | $31.68 |
9 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 176 | $14.30 |
| 80053 | Comprehensive metabolic panel | 0% | 49 | $0.00 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 0% | 94 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 66 | $0.00 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 58 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 50 | $0.00 |
| 86140 | 0% | 21 | $0.00 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 184 | $0.00 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 515 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHARMA, MADHUKAR (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Southern Plains Medical Center of Garvin County LLC | Pauls Valley, OK | $1.29M |
| Om Diagnostic Laboratories INC. | Norwood, MA | $1.05M |
| Forensic Stat Laboratory INC | Coral Springs, FL | $63K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.